High absolute coronary disease risk among turks: Involvement of risk factors additional to conventional ones

Cardiology

Volumn 115, Issue 4, 2010, Pages 297-306

  Onat, Altan ^a,b   Can, Günay ^c   Hergenç, Gülay ^d   Küçükdurmaz, Zekeriya ^f   Uǧur, Murat ^e   Yüksel, Hüsniye ^b  

^a Turkish Society of Cardiology   (Turkey)

^b Department of Cardiology ^*  (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^e DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^f Gaziantep Children Hospital   (Turkey)

Author keywords

Coronary disease risk prediction; Framingham risk score; Low grade inflammation; Obesity; Risk factors; Turkish population

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; ASIAN; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; FATALITY; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN DEFECT; RISK ASSESSMENT; SEX DIFFERENCE; TURKEY (REPUBLIC);

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX DISTRIBUTION; SMOKING; TRIGLYCERIDES; TURKEY;

EID: 77952007439     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000312009     Document Type: Article

References (32)

1. Onat A: Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10. (Pubitemid 32429589)
2. Onat A, Uysal Ö, Hergenç G: Assessment of the cohort of the Turkish Risk Factor Study with Framingham risk function: an additional indicator of the high absolute coronary risk among Turks (in Turkish). Turk Kardiyol Dern Ars 29: 208-214.
3. Onat A, Özhan H, Esen AM, Albayrak S, Karabulut A, Can G, Hergenç G: Prospective epidemiologic evidence of a protective effect of smoking on metabolic syndrome and diabetes among Turkish women - without associated overall health benefit. Atherosclerosis 2007; 193: 380-388. (Pubitemid 47058101)
4. Onat A, Herǧenç G, Uǧur M, Can G, Ordu S, Dursunoǧlu D: Lifestyle and metabolic determinants of incident hypertension, with special reference to cigarette smoking: a longitudinal population-based study. Am J Hypertens 2009; 22: 156-162.
5. Onat A, Hergenç G, Can G, Kücükdurmaz Z: Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. Obesity 2009; 17: 564-570.
6. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G: Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009; 58: 1393-1399.
7. Onat A, Hergenç G, Bulur S, Uǧur M, Kücükdurmaz Z, Can G: The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2009, E-pub ahead of print. doi: 10.1016/j.ijcard. 2008. 12. 066.
8. Onat A, Hergenç G, Ayhan E, Uǧur M, Kaya H, Tuncer M, Can G: Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor among Turks. Diabet Med 2009; 26: 981-988.
9. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847. (Pubitemid 28213628)
10. Liao Y, McGee DL, Cooper RS, Sutkowski MBE: How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J 1999; 137: 837-845. (Pubitemid 29226293)
11. Menotti A, Puddu PE, Lanti M: Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21: 365-370. (Pubitemid 30107553)
12. Ramachandran S, French JM, Vanderpump MPJ, Croft P, Neary RH: Using the Framingham model to predict heart disease in the United Kingdom. BMJ 2000; 320: 676-677.
13. Onat A, Şurdum-Avci G, Şenocak M, Örnek E, Gözükara Y: Plasma lipids and their interrelationship in Turkish adults. J Epidemiol Community Health 1992; 46: 470-476.
14. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
15. Rose GA, Blackburn H, Gillum RF, Prineas RJ: Cardiovascular Survey Methods, ed 2. Geneva, World Health Organization, 1982, pp 124-127.
16. D'Agostino RB Sr, Ramachandran SV, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117: 743-753. (Pubitemid 351640675)
17. Koller MT, Steyerberg EW, Wolbers M, Stijnen T, Bucher HC, Hunink MG, Witteman JC: Validity of the Framingham point scores in the elderly: results from the Rotterdam study. Am Heart J 2007; 154: 87-93. (Pubitemid 46920476)
18. Scheltens T, Verschuren WM, Boshuizen HC, Hoes AW, Zuithoff NP, Bots ML, Grobbee DE: Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age. Eur J Cardiovasc Prev Rehabil 2008; 15: 562-566.
19. Eichler K, Puhan MA, Steurer J, Bachmann LM: Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 2007; 153: 722-731. (Pubitemid 46628793)
20. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group: Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-187. (Pubitemid 32640849)
21. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB: The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the Health, Aging, and Body Composition cohort. Diabetes 2004; 53: 1068-1073. (Pubitemid 38436620)
22. Onat A, Ceyhan K, Baçar Ö, Erer B, Toprak S, Sansoy V: Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels - a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-292. (Pubitemid 35339372)
23. Onat A, Hergenç G, Can G: Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition (in Turkish). Anadolu Kardiyol Derg 2007; 7: 29-34.
24. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-414.
25. Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, Uchida K, Yajima J: Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 2008; 397: 42-47.
26. Kontush A, Chapman MJ: Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 2008; 8: 51-59.
27. Eroǧlu E, Bayrak F, Gemici G, Güneysu T, Mutlu B, Kalkan AK, Deǧertekin M: Prevalence of coronary artery disease in low to moderate-risk asymptomatic women: a multislice computed tomography study. Turk Kardiyol Dern Ars 2008; 36: 439-445.
28. Smith JD: Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol 2010; 30: 151-155.
29. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than highdensity lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108: 2751-2756.
30. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ: Highdensity lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008; 51: 634-642.
31. van Acker BAC, Botma GJ, Zwinderman AH, Koivenhoven JA, Dallinge-Thie GM, Sijbrands EJG, Boer JM, Seidell JC, Jukema JW, Kastelein JJ, Jansen H, Verhoeven AJ; RE-GRESS Study Group: High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesterol ester transfer protein and hepatic lipase gene variants. Atherosclerosis 2008; 200: 161-167.
32. Dodani S: Excess coronary artery disease risk in South Asian immigrants: can dysfunctional high-density lipoprotein explain increased risk? Vasc Health Risk Manag 2008; 4: 953-961.